PR Newswire/Les Echos/

Sanofi-aventis Press Release

Sanofi-aventis confirms its intent to reinforce its presence in the Russian
Federation via the "Pharmpolis Project"

  - Signing to take place at the Franco-Russian Intergovernmental Seminar -

Paris, France - November 27, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY)
announced today the signing of a Memorandum of Understanding with Prominvest, a
fully owned subsidiary of the Russian State Corporation Rostekhnologii,
confirming its intent to participate in the "Pharmpolis Project" using the new
modern sanofi-aventis insulin factory located in Russia as a pilot initiative.

The document was signed by Mikhail Shelkov, General Director of LLC Prominvest
and Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, during
the Franco-Russian Intergovernmental Seminar held in the Castle of Rambouillet,
France, in the presence of Vladimir Putin, Prime Minister of the Russian
Federation, and François Fillon, Prime Minister of France.

The "Pharmpolis Project" is part of the overall effort of the Russian Government
to localize innovative drug manufacturers in Russia, to attract high technology
platforms and to provide manufacturers with sufficient resources, effective
business environment and proper supplier network to foster the expansion of the
pharmaceutical market.

"Today represents an important milestone for sanofi-aventis in its commitment
and collaboration with the Russian Federation," declared Christopher A.
Viehbacher, Chief Executive Officer of sanofi-aventis. "We want to create a
situation in which patients suffering from severe conditions, such as diabetes,
are diagnosed and treated as early as possible and have access to innovative
drugs at affordable prices. The manufacturing of insulin locally will be a major
step towards achieving this goal."

"Diabetes is one of the Russian Federation's three major public health
priorities, with high mortality rates and affecting 2.5 million diagnosed Type 2
diabetes patients, according to the Russian National Diabetes Registry,"
declared S.V. Chemezov, General Director of the State Corporation
Rostekhnologii. if undiagnosed cases are taken into account, this figure is
estimated to be around 10 million people. Our aim is to fully satisfy Russia's
market demand for insulin and to do all our best to fight against such dangerous
and socially important disease, as diabetes".

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and
distributes therapeutic solutions to improve the lives of everyone.
Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
For more information, visit : www.sanofi-aventis.com

Forward Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include financial
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future events,
operations, products and services, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects,"
"anticipates," "believes," "intends," "estimates," "plans" and similar
expressions. Although sanofi-aventis' management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and generally
beyond the control of sanofi-aventis, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include those discussed or identified in the public filings with
the SEC and the AMF made by sanofi-aventis, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008.
Other than as required by applicable law, sanofi-aventis does not undertake any
obligation to update or revise any forward-looking information or statements.

Sanofi-aventis : www.sanofi-aventis.com
Media Relations: Tél. : (+) 33 1 53 77 44 50 - E-mail : MR@sanofi-aventis.com
Investor Relations : Tél. : (+) 33 1 53 77 45 45 - 
E-mail : IR@sanofi-aventis.com
                      
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication.